Literature DB >> 23495791

Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model.

S Sharmila1, I Christiana, P Kiran, M V R Reddy, K Sankaran, P Kaliraj.   

Abstract

As in many other parasitic diseases, efficacious vaccine for lymphatic filariasis has been elusive for want of new approaches leaving billions of people either debilitated or at risk. With multiple B- and T-cell epitopes, the abundant larval transcript-2 (ALT-2) of the filarial worm, Brugia malayi, has been shown to be a promising immunoprophylactic target. To enhance its efficacy, it was lipid modified using our recently developed protein engineering tool, which then offered 30% more immunoprotection (49 vs. 79%) in Mastomys coucha model. Sustained high levels of IFN-γ (about 100 times) and high antibody titres (10-fold) elicited by lipid-modified ALT-2, as compared to the native form, indicated the maintenance of Th1/Th2 balance that is impaired in filariasis. Thus, this study provides the basis for developing efficacious vaccines for filariasis and other parasitic diseases by exploiting bacterial lipid modification.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Brugia malayi; Mastomys; abundant larval transcript; bacterial lipid modification; immunoprophylaxis; lymphatic filariasis

Mesh:

Substances:

Year:  2013        PMID: 23495791     DOI: 10.1111/pim.12034

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  2 in total

1.  Bacterial Lipid Modification of ICP11 and a New ELISA System Applicable for WSSV Infection Detection.

Authors:  Vidhyapriya Murugan; Krishnan Sankaran
Journal:  Mar Biotechnol (NY)       Date:  2018-04-14       Impact factor: 3.619

2.  The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.

Authors:  Alice Halliday; Joseph D Turner; Ana Guimarães; Paul A Bates; Mark J Taylor
Journal:  Parasit Vectors       Date:  2016-02-20       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.